Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00526669 · ClinicalTrials.gov registry record · Phase 2
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00526669 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 68 participants.
The verdict
NCT00526669, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The study will determine if changes in expression of markers involved in the 5-FU pathways are associated with response to treatment with the combination of lapatinib and capecitabine independent of tumor erbB2 status.
Interventions
- DRUG Lapatinib and Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2008-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00526669
The ClinicalTrials.gov registry entry for NCT00526669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lapatinib and Capecitabine is the first listed.
NCT00526669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00526669 about?
NCT00526669 is a clinical study titled "Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib". The study will determine if changes in expression of markers involved in the 5-FU pathways are associated with response to treatment with the combination of lapatinib and capecitabine independent of tumor erbB2 status.
What is the current status of trial NCT00526669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2008-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00526669?
The interventions under investigation include: Lapatinib and Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00526669?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.